Stock price performance of Biocept, Inc. is analyzed for various periods using several stock trading signals. In this case, The stock price has rallied 84.34% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -1.55% . Looking at the past 52 week period, the stock price is down -66.67% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Biocept, Inc. has a negative value of -79.98 compared to overall market performance. The stock has recorded a 20-day Moving Average of 9.57% and the 50-Day Moving Average is 43.84%.The 200 Day SMA reached 80.61%
Biocept, Inc. is having a Relative Strength Index of 53.85 which indicates the stock is not yet over sold or over bought based on the technical indicators. Biocept, Inc. (NASDAQ:BIOC) has tumbled 1.92% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 61.05% in the last four weeks. The stocks have underperformed the S&P 500 by 2.04% during the past week but Biocept, Inc. (NASDAQ:BIOC) it has outperformed the index in 4 weeks by 59.62%.
Company has reported several Insider transactions to the SEC, on Oct 21, 2016, Michael W. Nall (CEO) purchased 36,363 shares at 1.10 per share price.On Oct 21, 2016, Marsha Alpert Chandler (director) purchased 4,545 shares at 1.10 per share price.On Oct 21, 2016, Timothy Kennedy (CFO) purchased 36,363 shares at 1.10 per share price.
Biocept, Inc. (NASDAQ:BIOC) : On Friday heightened volatility was witnessed in Biocept, Inc. (NASDAQ:BIOC) which led to swings in the share price. The stock opened for trading at $1.4 and hit $1.65 on the upside , eventually ending the session at $1.53, with a gain of 10.07% or 0.14 points. The heightened volatility saw the trading volume jump to 2,851,372 shares. The 52-week high of the share price is $5.640005 and the company has a market cap of $27 million. The 52-week low of the share price is at $0.7401 .
Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California.